Intellia Therapeutics Inc
F:38I
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Intellia Therapeutics Inc
F:38I
|
US |
|
A
|
Airbus SE
SWB:AIR
|
NL |
|
Sumitomo Realty & Development Co Ltd
TSE:8830
|
JP |
|
AAR Corp
NYSE:AIR
|
US |
Intellia Therapeutics Inc
Intellia Therapeutics is a biotechnology company that develops gene-editing medicines based on CRISPR technology. Its goal is to fix disease at the DNA level, especially for rare inherited disorders and some other serious conditions. The company is not a drug seller with a large commercial product line; it is mainly a research and development company trying to turn gene editing into approved treatments. Intellia’s main customers are not patients directly. Its business depends on hospitals, doctors, regulators, and, for some programs, partner companies that help fund or advance development. The company makes money mostly through collaboration and licensing arrangements, research funding from partners, and, if its medicines are approved, future sales or royalties tied to those products. What makes Intellia different is that it is building medicines designed to edit genes inside the body rather than only treat symptoms. That puts it in a highly specialized part of biotech where success depends on proving that gene editing can be both effective and safe. The company’s role is to invent and test these therapies, then work with partners and regulators to bring them to market.
Intellia Therapeutics is a biotechnology company that develops gene-editing medicines based on CRISPR technology. Its goal is to fix disease at the DNA level, especially for rare inherited disorders and some other serious conditions. The company is not a drug seller with a large commercial product line; it is mainly a research and development company trying to turn gene editing into approved treatments.
Intellia’s main customers are not patients directly. Its business depends on hospitals, doctors, regulators, and, for some programs, partner companies that help fund or advance development. The company makes money mostly through collaboration and licensing arrangements, research funding from partners, and, if its medicines are approved, future sales or royalties tied to those products.
What makes Intellia different is that it is building medicines designed to edit genes inside the body rather than only treat symptoms. That puts it in a highly specialized part of biotech where success depends on proving that gene editing can be both effective and safe. The company’s role is to invent and test these therapies, then work with partners and regulators to bring them to market.
HAE Program Progress: Intellia completed enrollment in the Phase III HAELO trial for Lonvo-z ahead of schedule, with strong interest from both patients and physicians.
Regulatory Milestone: The FDA lifted the clinical hold on the MAGNITUDE-2 (polyneuropathy) trial for Nex-z, allowing enrollment to resume, while work continues with the FDA to lift the hold on the MAGNITUDE (cardiomyopathy) study.
Financial Position: Intellia ended 2025 with $605.1 million in cash, expected to fund operations into the second half of 2027 and beyond key milestones.
Q4 Results: Collaboration revenue rose to $23 million and net loss decreased to $95.8 million compared to the prior year quarter.
Commercial Outlook: Company is preparing for commercial launch of Lonvo-z, highlighting its onetime therapy and potential for significant cost savings versus chronic HAE treatments.
Safety Measures: New protocols, including additional liver tests and steroid use, have been implemented in trials to mitigate immune-mediated liver enzyme elevations.
Guidance: Top-line Phase III data for Lonvo-z expected mid-2026, with BLA submission planned for the second half of 2026.
